What is Terlipressin & then Dummy used for?

Terlipressin & then Dummy is indicated for Acute variceal bleeding in portal hypertension, Hepatorenal syndrome (Type 1).

Who makes Terlipressin & then Dummy?

Terlipressin & then Dummy is developed by Aga Khan University.

What development phase is Terlipressin & then Dummy in?

Terlipressin & then Dummy is FDA-approved (marketed).

What are the side effects of Terlipressin & then Dummy?

Common side effects include Abdominal pain, Diarrhea, Hypertension, Myocardial ischemia, Nausea.

Last reviewed 2026-04-22 · How we verify

Terlipressin & then Dummy

Aga Khan University · FDA-approved active Small molecule Quality 2/100

Terlipressin is a vasopressin analog that selectively activates V1 receptors on vascular smooth muscle to cause vasoconstriction and reduce portal pressure.

Terlipressin, marketed by Aga Khan University, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Terlipressin & then Dummy
Also known as	Novapressin
Sponsor	Aga Khan University
Drug class	Vasopressin analog
Target	Vasopressin V1 receptor
Modality	Small molecule
Therapeutic area	Gastroenterology / Hepatology
Phase	FDA-approved

Mechanism of action

Terlipressin binds to vasopressin V1 receptors on blood vessels, causing splanchnic vasoconstriction and reducing portal venous pressure. This mechanism is particularly useful in portal hypertension-related bleeding and hepatorenal syndrome, where it improves renal perfusion and reduces variceal bleeding risk. The drug has greater V1 selectivity compared to native vasopressin, resulting in fewer systemic side effects.

Approved indications

Acute variceal bleeding in portal hypertension
Hepatorenal syndrome (Type 1)

Common side effects

Abdominal pain
Diarrhea
Hypertension
Myocardial ischemia
Nausea

Key clinical trials

Short Course Terlipressin for Control of Acute Variceal Bleeding (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Terlipressin & then Dummy CI brief — competitive landscape report
Terlipressin & then Dummy updates RSS · CI watch RSS
Aga Khan University portfolio CI